Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3results about How to "Effective targeting" patented technology

A controllable cryogenic treatment preparation of mesenchymal stem cells, its preparation method and application

PendingCN122081216Aresponse blockingreduce excessive depositionSkeletal/connective tissue cellsUnknown materialsFibrosisDigestion
This invention relates to the field of biomedical technology and provides a controllable cryogenic treatment mesenchymal stem cell preparation, its preparation method, and its application. The method includes the following steps: cell preparation and cryopreservation equilibration: digestion and collection; cryopreservation equilibration; removal of cryoprotectant and washing: centrifugation to remove cryopreservation solution; PBS washing; cryogenic incubation: resuspending the final cell pellet after multiple washes in pre-cooled PBS; incubating the cell suspension at 4±0.5℃ for 72 hours±10 minutes; after incubation, removing the cell suspension from the 4℃ environment, centrifuging, and resuspending in PBS. This invention yields a ready-to-use, easily stored and transported, and functionally enhanced RT-MSCs preparation. Although the cells in this preparation have lost their proliferative and metabolic activity, they still retain the complete therapeutic functions of MSCs, such as immunomodulation, anti-fibrosis, and angiogenesis promotion.
Owner:JILIN UNIVERSITY

A drug delivery nanomaterial encapsulating a cell membrane and its preparation method

This invention relates to the field of pancreatic cancer drug technology, and discloses a drug delivery nanomaterial encapsulating a cell membrane and its preparation method. The preparation method includes: dissolving PLGA, a sonosensitive agent IR780, and an immunoadjuvant R837 in a mixed organic solvent of dichloromethane and ethanol to form an oil phase; adding the oil phase to a PVA aqueous solution, ultrasonically emulsifying to form an emulsion, then adding an isopropanol aqueous solution, stirring and solidifying, and removing the organic solvent to obtain drug-loaded nanoparticles IR780 / R837@PLGA; finally, mixing the drug-loaded nanoparticles with the cell membrane of Panc02 pancreatic cancer cells in DEPC water and ultrasonically treating to obtain the drug delivery nanomaterial M-IR780 / R837@PLGA encapsulated by the cell membrane of Panc02 pancreatic cancer cells. This material can effectively target pancreatic tumors and prolong their in vivo circulation time, thereby enhancing the targeted therapy and immunotherapy effects of pancreatic cancer.
Owner:ZHEJIANG UNIV OF TECH

Nanomaterials targeting driving resuscitation of dying cells and preparation method and application thereof

PendingCN122251440Aeffective targetingimprove defectsMuscular disorderAntinoxious agentsTissue repairSpinal cord lesion
The application discloses a nano material for targeting and driving resuscitation of dying cells, and a preparation method and application thereof. The nano material is a nano platelet vesicle with phosphatidylserine exposed to the outer layer of the membrane after nanoization and centrifugal treatment. The material is obtained by separating and enriching platelets from peripheral blood, then nanoizing the platelets, and then inducing the phosphatidylserine on the platelet membrane to evert through high-speed centrifugation. The material is used for preparing a medicine for promoting tissue repair, and the medicine promotes resuscitation of dying cells by targeting the dying cells and enhancing the membrane repair capacity of the dying cells, so as to promote tissue repair, including repair of orthopedic, muscle, skin, spinal cord or visceral tissue, especially repair of diabetic foot, skin avulsion injury, ischemic skin flap or spinal cord injury. The resuscitation of dying cells is promoted successfully without intervention of lysis programmed cell death initiation, so that the problems of off-target effect and treatment paradox existing in current mainstream small molecule inhibitor strategy are effectively solved.
Owner:THE AFFILIATED SIR RUN RUN SHAW HOSPITAL OF SCHOOL OF MEDICINE ZHEJIANG UNIV